ConductScience.org, home

Paper30739743

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet, 2019. Cited by 328 papers, by iCite.

Cite this record

ConductScience Library. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Papers, record 30739743. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30739743

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
PubMed
Journal
Lancet
PubMed
Year
2019
PubMed
Publication types
Journal Article, Meta-Analysis
PubMed
Citations, by iCite
328
iCite
Relative citation ratio, by iCite
12
iCite
Revised in PubMed
2026-05-18
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Group

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Breast NeoplasmsMajor topic
Drug Administration Schedule
Female
Humans

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
MC_U137686858Medical Research CouncilUnited KingdomPubMedPubMed
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMedNIH RePORTER
25351Cancer Research UKUnited KingdomPubMedPubMed
MC_UU_12026/1Medical Research CouncilUnited KingdomPubMedPubMed
21133Cancer Research UKUnited KingdomPubMedPubMed
UL1 TR000371NCATS NIH HHSUnited StatesUL1TR000371PubMed and NIHNIH RePORTER
MC_U137686850Medical Research CouncilUnited KingdomPubMedPubMed
27691Cancer Research UKUnited KingdomPubMedPubMed

Download CSV of grants

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00798070Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer PatientsBackgroundClinicalTrials.gov
NCT06190600Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant ChemotherpyBackgroundClinicalTrials.gov
NCT07521397Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.BackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in31741891Improving chemotherapy outcome in early breast cancer.https://conductscience.org/library/papers/31741891PubMed
Comment in32132126Shorter intervals and sequential administration of adjuvant chemotherapy are effective in reducing the 10-year risk of recurrence and death in early breast cancer women without detrimental effects.https://conductscience.org/library/papers/32132126PubMed

Download CSV of comments and corrections

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111818200Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients.Eur J Cancer2002https://conductscience.org/library/papers/11818200PubMed
212610183
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
J Clin Oncol2003https://conductscience.org/library/papers/12610183PubMed
312637460Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.J Clin Oncol2003https://conductscience.org/library/papers/12637460PubMed
415837983
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
J Clin Oncol2005https://conductscience.org/library/papers/15837983PubMed
515894097Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet2005https://conductscience.org/library/papers/15894097PubMed
618182617Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.J Natl Cancer Inst2008https://conductscience.org/library/papers/18182617PubMed
719103732Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.J Clin Oncol2009https://conductscience.org/library/papers/19103732PubMed
819364964Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.J Clin Oncol2009https://conductscience.org/library/papers/19364964PubMed
919901117
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
J Clin Oncol2010https://conductscience.org/library/papers/19901117PubMed
1020519679Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.N Engl J Med2010https://conductscience.org/library/papers/20519679PubMed
1122152853Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.Lancet2012https://conductscience.org/library/papers/22152853PubMed
1222733553Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.EMBO Mol Med2012https://conductscience.org/library/papers/22733553PubMed
1323940225Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.J Clin Oncol2013https://conductscience.org/library/papers/23940225PubMed
1425422488SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.J Clin Oncol2015https://conductscience.org/library/papers/25422488PubMed
1525740286Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.Lancet2015https://conductscience.org/library/papers/25740286PubMed
1625919529Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.JAMA2015https://conductscience.org/library/papers/25919529PubMed
1726077235Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.J Clin Oncol2015https://conductscience.org/library/papers/26077235PubMed
1826211827Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.Lancet2015https://conductscience.org/library/papers/26211827PubMed
1926940688Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.Ann Oncol2016https://conductscience.org/library/papers/26940688PubMed
2027825007Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.JAMA2016https://conductscience.org/library/papers/27825007PubMed

See all 28 referencesDownload CSV of references

Cited by199

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 328 citations.

PMIDTitleJournalYearIn PapersSource
42967914Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS).Signal Transduct Target Ther2026https://conductscience.org/library/papers/42967914PubMed
42938878Cardiovascular Magnetic Resonance for Early Detection of Cancer Therapy-Related Cardiac Dysfunction: From Multiparametric Tissue Signatures to Clinical Pathways.Cancers (Basel)2026https://conductscience.org/library/papers/42938878PubMed
42920438Case Report: Ribociclib-associated bilateral neurotrophic keratitis requiring amniotic membrane transplantation during adjuvant treatment of early breast cancer.Front Oncol2026https://conductscience.org/library/papers/42920438PubMed
42826677Effect of dose-dense adjuvant chemotherapy in patients with node-positive early breast cancer according to estrogen receptor levels: an exploratory analysis of the GIM2 trial.Breast2026https://conductscience.org/library/papers/42826677PubMed
42743833Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal.Breast2026https://conductscience.org/library/papers/42743833PubMed
42731007[Anthracycline use in breast cancer based on our current knowledge].Magy Onkol2026https://conductscience.org/library/papers/42731007PubMed
42630843Cytoskeletal dynamics in breast cancer: mechanistic insights and therapeutic opportunities.J Natl Cancer Cent2026https://conductscience.org/library/papers/42630843PubMed
42602220Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.Ther Adv Med Oncol2026https://conductscience.org/library/papers/42602220PubMed
42544249Neoadjuvant Chemotherapy Response in Breast Cancer among Nigerian Women: A Systematic Review and Meta-Analysis (2000-2025).Niger Med J2026https://conductscience.org/library/papers/42544249PubMed
42528614Efficacy and safety of bupleurum-containing formulas combined with chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.Front Oncol2026https://conductscience.org/library/papers/42528614PubMed
42500284Machine learning-based prognostic model for triple-negative breast cancer with axillary lymph node metastasis.Front Oncol2026https://conductscience.org/library/papers/42500284PubMed
42364416Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.Breast2026https://conductscience.org/library/papers/42364416PubMed
42279302Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Literature Overview.Cancers (Basel)2026https://conductscience.org/library/papers/42279302PubMed
42189890Sensitivity to Endocrine Therapy Index Predicts Benefit from Weekly Adjuvant Paclitaxel for Hormone Receptor-Positive Breast Cancer in the GEICAM/9906 Trial.Clin Cancer Res2026https://conductscience.org/library/papers/42189890PubMed
42073623Impact of Neoadjuvant Chemotherapy Administration Time of Day on Pathological Response in Patients with Early Triple-Negative Breast Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42073623PubMed
41959917Development and validation of a machine learning model for predicting unplanned removal of totally implantable venous access ports in patients with breast cancer.Front Oncol2026https://conductscience.org/library/papers/41959917PubMed
41949990Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis.Ann Med2026https://conductscience.org/library/papers/41949990PubMed
41832961Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.JNCI Cancer Spectr2026https://conductscience.org/library/papers/41832961PubMed
41782330Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.J Natl Cancer Inst2026https://conductscience.org/library/papers/41782330PubMed
41754767Method-Comparison Validation of a Novel Capillary Blood Collection Kit, True Dose® TD-EPI, for Therapeutic Drug Monitoring of Epirubicin.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/41754767PubMed

See all 199 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
PGR5241PubTator's text mininghttps://conductscience.org/library/genes/5241NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30739743

GET https://conductscience.org/api/papers/v1/30739743/references?page=2